Sugi Predict

Sugi Predict / Compounds / Fronepidil

Fronepidil

Fronepidil

SCHEMBL2109579

C#CC(C)(OCC(COCC(C)C)N1CCCC1)c1ccccc1

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 9/20 0.47
▸ CYP2C19 P33261 8/20 0.47
▸ CYP2D6 P10635 7/20 0.47
▸ KCNH2 Q12809 6/20 0.47
▸ CYP1A2 P05177 5/20 0.47
▸ CYP2C9 P11712 5/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ LMNA P02545 3/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ CHRM1 P11229 2/20 0.47
▸ SLC6A2 P23975 2/20 0.47
▸ SLC6A4 P31645 2/20 0.47
▸ ADRA1A P35348 2/20 0.47
▸ OPRM1 P35372 2/20 0.47
▸ DRD3 P35462 2/20 0.47
▸ SLC6A3 Q01959 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ TSHR P16473 1/20 0.47
▸ HIF1A Q16665 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7272326 0.85 KMT2A (0.41) CYP3A4CYP2C19CYP2D6KCNH2KMT2A
SCHEMBL7263527 0.80 CYP3A4 (0.35) CYP3A4CYP2C19CYP2D6KCNH2CYP1A2
SCHEMBL1152269 0.69 CYP3A4 (0.50) CYP3A4CYP2C19CYP2D6KCNH2CYP1A2
SCHEMBL8847011 0.68 MAPK1 (0.38) CYP3A4CYP2C19LMNAMAPTALDH1A1
SCHEMBL10580462 0.66 LMNA (0.48) CYP3A4CYP2C19CYP2D6KCNH2CYP1A2
SCHEMBL10808194 0.65 POLB (0.50) CYP2D6KMT2ALMNAMEN1MAPT
SCHEMBL10575808 0.65 PTGS1 (0.49) CYP3A4CYP2C19CYP2D6KCNH2CYP1A2
Hydrochloric Acid SCHEMBL10579200 0.65 LMNA (0.49) CYP3A4CYP2C19CYP2D6KCNH2CYP1A2
SCHEMBL10588681 0.65 LMNA (0.44) CYP3A4CYP2C19CYP2D6KCNH2CYP1A2
SCHEMBL10675580 0.64 KCNH2 (0.77) CYP3A4CYP2C19CYP2D6KCNH2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 — — US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 — — US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 — — US disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US disclosed
US-20140154313-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2014-06-05 — — US disclosed
EP-2717860-A1 CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION STI Pharma, LLC (US) 2014-04-16 — — EP disclosed
US-8454582-B2 Methods and devices for the treatment of ocular conditions SURMODICS, INC. (US) 2013-06-04 — — US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 — — US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 — — US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 — — US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 — — US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 — — US disclosed
US-4430332-A ANGINA PECTORIS CENTRE EUROPEEN DE RECHERCHES MAUVERNAY (FR) 1984-02-07 — — US disclosed
EP-0031771-A1 1-(2-Propynyloxy)-2-amino-3-propanol ethers, their preparation and pharmaceutical composition containing them RIOM LABORATOIRES- C.E.R.M. (Société Anonyme) (FR) 1981-07-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 CYP3A4 4863/4885CYP2C19 4874/4885CYP2D6 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.